Monotherapy With Levetiracetam or Carbamazepine in Patients Suffering From Epilepsy.

• Status: Completed
• Trial end date: 2005-11-01
• Target enrollment: 0
• Participant gender: All

Summary

A double-blind follow-up trial assessing the long term safety of Levetiracetam as per adverse events reporting, physical and neurological examination and vital signs

• Phase: Phase 3

Details

• Lead Sponsor: UCB Pharma
• Treatments: Carbamazepine; Etiracetam; Levetiracetam; Piracetam

Criteria

Inclusion Criteria:

• Subjects with a confirmed diagnosis of epilepsy.

• Subjects having experienced in the past unprovoked partial seizures (IA, IB, IC with clear focal origin), or generalized tonic-clonic seizures (without clear focal origin), that are classifiable according to the International Classification of Epileptic Seizures

• Subjects coming from the N01061 monotherapy trial and for whom double-blind continuation of investigational product is beneficial.

Exclusion Criteria:

• Need for an additional AED.